A tumor-targeted heptamethine cyanine dye induces suppression of progesterone receptor activity to treat hormone receptor-positive breast cancer
Year: 2025
Type: article
Abstract: Background: A primary treatment of hormone receptor-positive breast cancer is the pharmacological inhibition of hormone receptors by blocking the effects of estrogen and/or progesterone.Methods: In MCF-7 xenograft tumors known as estrogen-sensitive breast cancer, a hydrophilic near-infrared (NIR) heptamethine cyanine dye (named CA800-PR) induced Golgi fragmentation and suppressed only progesterone receptor protein expression, regardless of estrogen receptors.Results: In this study, CA800-PR was newly developed for the treatment of hormone receptor-positive breast cancer unlike conventional drugs such as tamoxifen and aromatase inhibitors.Since the intracellular stress induced by CA800-PR led to the production of pro-inflammatory cytokines, we confirmed a significant increase in the presence of antitumor/pro-inflammatory MHC class II + CD80 + M1-type macrophages during the course of treatment.Comparing with the traditional hormone therapies aimed at controlling tumor growth or preventing recurrence post-surgery, the tumor-targeted NIR fluorescent dye CA800-PR alone can be effectively used as a multifunctional antitumor agent directly inducing apoptosis in both MCF-7 cells and xenograft tumors.Conclusion: This work provides a promising alternative to hormone therapy-related breast cancer for future clinical applications.
Source: Theranostics
DOI: 10.7150/thno.126396
Authors: Yoonbin Park, Sang-Hyo Kim, Moon Suk Kim, Hoon Hyun
Institutions: Chonnam National University, Ajou University
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,671
Award: G603344095
OpenAlex ID: W4417453453
